200
Participants
Start Date
September 13, 2022
Primary Completion Date
August 31, 2028
Study Completion Date
August 31, 2029
Ribociclib
400 mg orally once daily Days 1-21 (28 day Cycle)
Fulvestrant
500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
Anastrozole
1 mg orally once daily
Letrozole
2.5 mg orally once daily
Exemestane
25 mg orally once daily
RECRUITING
New York University Clinical Cancer Center, New York
RECRUITING
Penn State Cancer Institute, Hershey
RECRUITING
University of Virginia Health System, Charlottesville
RECRUITING
Virginia Commonwealth University, Richmond
RECRUITING
Orlando Health Cancer Institute, Orlando
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
Ohio State University Comprehensive Cancer Center, Columbus
RECRUITING
Parkview Research Center, Fort Wayne
RECRUITING
University of Michigan Health System, Ann Arbor
TERMINATED
University of Michigan Health-West, Wyoming
RECRUITING
University of Iowa Hospitals and Clinics, Iowa City
RECRUITING
University of Wisconsin, Madison
RECRUITING
University of Illinois Cancer Center, Chicago
RECRUITING
University of Nebraska Medical Center, Omaha
RECRUITING
University of Arizona, Phoenix
RECRUITING
Providence Portland Medical Center, Portland
RECRUITING
Tufts Medical Center, Boston
RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Oana Danciu
OTHER